Barcelona, Spain—Results of the new clinical trial RADICALS-RT indicate that using salvage radiotherapy immediately after surgery leads to equivalent outcomes in terms of progression-free survival (PFS) versus adjuvant radiotherapy in men with prostate cancer undergoing radical prostatectomy. These late-breaking results were presented at the ESMO Congress 2019 by lead investigator Chris Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, England.
Orlando, FL—Chimeric antigen receptor (CAR) T-cell therapy is now approved as third-line treatment for patients with B-cell lymphomas and leukemias. For some patients, CAR T-cell therapy is a miracle therapy, extending survival and, in some cases, as a bridge to a potentially curative transplant. But at an estimated cost of $375,000 to $475,000 per person, many people have questioned the value of this treatment, and whether it can be delivered effectively to patients not enrolled in clinical trials.
In 2 independent studies presented at the 2018 American Association for Cancer Research Annual Meeting, chlamydia trachomatis infection was shown to increase the risk for developing ovarian cancer by approximately 2-fold.
At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial, which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer
Aggressive end-of-life care for patients with terminal cancer and other illnesses is costly and not recommended.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.